Pneumococcal Vaccines Market Size and Forecast

The global Pneumococcal Vaccines Market was valued at USD 10.2 Billion in 2022 and is projected to reach USD 16.4 Billion by 2030, growing at a CAGR of 6.1% from 2024 to 2030. The increasing prevalence of pneumococcal diseases, combined with rising awareness about the importance of vaccination, is a significant factor driving the market growth. The growing geriatric population and the higher incidence of pneumonia and other pneumococcal infections are also contributing to the demand for pneumococcal vaccines, particularly in regions with aging populations. Furthermore, advancements in vaccine technology and the introduction of more effective and affordable vaccines are expected to fuel market expansion during the forecast period.

In addition, the increasing government and healthcare initiatives to combat pneumococcal diseases, especially in low- and middle-income countries, is anticipated to drive the market forward. The market is expected to witness robust growth due to the rising adoption of immunization programs and the need for improved healthcare infrastructure globally. The development of new vaccines, the expansion of vaccine coverage, and the increasing recommendation of pneumococcal vaccination by health organizations will further support the growth trajectory of the pneumococcal vaccines market in the coming years.

Download Full PDF Sample Copy of Market Report @

Pneumococcal Vaccines Market Research Sample Report

Pneumococcal Vaccines Market By Application

The pneumococcal vaccines market by application has been segmented into distinct categories based on age groups and risk factors. These include vaccines targeted at specific groups such as infants, children (ages 2-10), adults (ages 10-64), and the elderly (65 years and above). Each segment has unique needs based on age, immune system development, and vulnerability to pneumococcal diseases, which affects the demand and distribution of vaccines. A better understanding of these applications enables more effective health interventions and targeted strategies for vaccine distribution globally.

For Infants

Vaccination of infants is a critical segment in the pneumococcal vaccines market, as this age group is particularly vulnerable to severe pneumococcal diseases, including pneumonia, meningitis, and sepsis. The immune system of infants is still developing, which makes them more susceptible to infections. Consequently, the vaccination schedule for infants is a priority in many countries' immunization programs. The introduction of conjugate vaccines, such as the 13-valent pneumococcal conjugate vaccine (PCV13), has shown a significant reduction in the incidence of pneumococcal diseases among infants and has become a cornerstone in global vaccination programs. This vaccination helps build immunity early in life and reduces the burden of severe infections during the formative years of development.

In addition to the prevention of pneumococcal diseases, vaccinating infants also reduces the risk of disease transmission within communities. This application is especially important in low-income countries where pneumococcal infections remain a leading cause of mortality among young children. The global effort to introduce and sustain vaccination programs for infants has led to a marked decline in morbidity and mortality rates related to these infections. Health organizations like the World Health Organization (WHO) continue to advocate for increased access to pneumococcal vaccines for infants as part of routine immunization schedules worldwide.

For Children (2-10 years)

The pneumococcal vaccines for children aged 2 to 10 years are formulated to build on the immune foundation established in infancy while addressing the ongoing vulnerability to pneumococcal infections. By this age, children are still at risk for infections, particularly those in daycare or school settings where disease transmission is more common. While the immune system of children in this age group is more developed than infants, they may still require additional protection due to increased exposure to bacteria. Vaccination programs for children in this age group typically involve booster doses to ensure sustained protection against invasive pneumococcal disease (IPD).

As children are increasingly exposed to environmental risks and pathogens, particularly in educational settings, vaccination becomes a vital tool in reducing overall disease burden. The use of pneumococcal vaccines in children has led to a decline in hospitalizations due to pneumonia and other severe complications associated with pneumococcal infections. Continued awareness and vaccination campaigns are essential to further reduce the incidence of these diseases. The market is expected to expand further as more countries adopt or strengthen immunization programs that include pneumococcal vaccines for children, ensuring long-term public health benefits.

For Persons (10-64 years)

The pneumococcal vaccines market for adults aged 10-64 years focuses on individuals who may not be as vulnerable as infants or the elderly but still face a risk due to lifestyle factors or underlying health conditions. Individuals in this age group who are smokers, suffer from chronic diseases such as asthma, diabetes, or cardiovascular conditions, or have weakened immune systems, are at a higher risk for pneumococcal diseases. Vaccination for these individuals is crucial in preventing serious health complications and hospitalizations. Adults in this age group are often targeted by vaccination programs, particularly in regions where the burden of pneumococcal diseases is still high.

Pneumococcal vaccination in this demographic often involves the 23-valent pneumococcal polysaccharide vaccine (PPSV23), which targets a broader range of pneumococcal strains. The market for vaccines in this segment is driven by increasing awareness about the importance of vaccination in adult populations, particularly among high-risk groups. As people live longer, the healthcare burden shifts, and vaccinations in this group help reduce the occurrence of preventable diseases, improve overall health outcomes, and reduce healthcare costs. Public health policies focusing on this age group are expected to continue to grow as awareness increases about the benefits of vaccination for adults in the broader population.

For The Elderly (65+ years)

The elderly population (65 years and above) is the most vulnerable group in the pneumococcal vaccines market. Aging weakens the immune system, and individuals over 65 are at a significantly higher risk for pneumococcal diseases, including pneumonia, meningitis, and bloodstream infections. As a result, pneumococcal vaccines play a pivotal role in preventing severe illness and death among this age group. Vaccination programs typically offer the 13-valent conjugate vaccine (PCV13) and the 23-valent polysaccharide vaccine (PPSV23) for older adults to ensure comprehensive protection. Given the aging global population, demand for pneumococcal vaccines for the elderly is expected to grow substantially in the coming years.

Vaccination of older adults also helps reduce the strain on healthcare systems by decreasing hospitalizations and associated healthcare costs. Studies have shown that pneumococcal vaccines significantly lower the incidence of pneumococcal pneumonia, a leading cause of hospitalization among the elderly. The global trend of increasing life expectancy, coupled with the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, further underscores the need for effective pneumococcal vaccination strategies targeted at older adults. As such, this segment remains a key focus for public health campaigns and vaccine manufacturers looking to expand their offerings in the market.

Key Trends and Opportunities in the Market

The pneumococcal vaccines market is experiencing several key trends that present significant opportunities for growth. One of the primary trends is the increasing focus on expanding vaccine access to underserved and low-income populations. Efforts by organizations such as the World Health Organization and GAVI, the Vaccine Alliance, are helping to make pneumococcal vaccines more widely available to children and adults in developing countries. As more nations include pneu

For More Information or Query, Visit @ Pneumococcal Vaccines Market Size And Forecast 2025-2030